The European Commission authorized Johnson & Johnson's Lazcluze and Rybrevant combination therapy for first-line treatment of specific NSCLC cases, showing significant efficacy compared to Tagrisso. This approval challenges Tagrisso's dominance in the market, with promising sales forecasts for the new combination therapy.